Pathology: Extensive stage SCLC (Es-SCLC) - maintenance (M);
| Extensive stage SCLC (Es-SCLC) - maintenance (M) | |||
| CheckMate 451 (N ; all population), 2019 | CheckMate 451 (NI ; all population), 2019 | ||
| nivolumab alone | 1 | T1 | |
| nivolumab plus ipilimumab | 1 | T1 | |
| placebo | 0 | T0 | T0 |